Cover Image

Stopping azithromycin mass drug administration for trachoma: A systematic review.

The World Health Organization (WHO) recommends continuing azithromycin mass drug administration (MDA) for trachoma until endemic regions drop below 5% prevalence of active trachoma in children aged 1-9 years. Azithromycin targets the ocular strains of Chlamydia trachomatis that cause trachoma. Regio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hamidah Mahmud (Author), Emma Landskroner (Author), Abdou Amza (Author), Solomon Aragie (Author), William W Godwin (Author), Anna de Hostos Barth (Author), Kieran S O'Brien (Author), Thomas M Lietman (Author), Catherine E Oldenburg (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2021-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
by: Jonathan D King, et al.
Published: (2014)

Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops.
by: Abdou Amza, et al.
Published: (2010)

A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.
by: Sheila K West, et al.
Published: (2013)

Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma.
by: Michael Marks, et al.
Published: (2016)

Mass treatment with azithromycin for trachoma control: participation clusters in households.
by: Elizabeth N Ssemanda, et al.
Published: (2010)

Changes in trachoma indicators in Kiribati with two rounds of azithromycin mass drug administration, measured in serial population-based surveys.
by: E Brook Goodhew, et al.
Published: (2023)

Impact of Community Mass Treatment with Azithromycin for Trachoma Elimination on the Prevalence of Yaws.
by: Michael Marks, et al.
Published: (2015)

Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia.
by: Sarah E Burr, et al.
Published: (2013)

Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal
by: Holm Susan Osaki, et al.
Published: (2001)

Prevalence of trachoma in the Kayes region of Mali eight years after stopping mass drug administration.
by: Lamine Traoré, et al.
Published: (2018)

Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia.
by: Tigist Astale, et al.
Published: (2018)

The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children
by: Harry Pickering, et al.
Published: (2022)

Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
by: Emma M Harding-Esch, et al.
Published: (2013)

A cross-sectional study of 'yaws' in districts of Ghana which have previously undertaken azithromycin mass drug administration for trachoma control.
by: Rosanna Ghinai, et al.
Published: (2015)

Linear growth in preschool children treated with mass azithromycin distributions for trachoma: A cluster-randomized trial.
by: Jeremy D Keenan, et al.
Published: (2019)

Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors.
by: Tansy Edwards, et al.
Published: (2014)

To eliminate trachoma: Azithromycin mass drug administration coverage and associated factors among adults in Goro district, Southeast Ethiopia.
by: Tadele Feyisa, et al.
Published: (2022)

Correction: Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma.
by: PLOS Neglected Tropical Diseases Staff
Published: (2018)

To eliminate trachoma: Azithromycin mass drug administration coverage and associated factors among adults in Goro district, Southeast Ethiopia
by: Tadele Feyisa, et al.
Published: (2022)

Correction: Mass Treatment with Azithromycin for Trachoma: When Is One Round Enough? Results from the PRET Trial in The Gambia.
by: Emma M. Harding-Esch, et al.
Published: (2013)

Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.
by: Jessica S Kim, et al.
Published: (2019)

Concordance of ompA types in children re-infected with ocular Chlamydia trachomatis following mass azithromycin treatment for trachoma.
by: Arman Mosenia, et al.
Published: (2022)

Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma
by: Fraser-Hurt Nicole, et al.
Published: (2001)

Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
by: Athumani M Ramadhani, et al.
Published: (2019)

Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana
by: Solomon Anthony W., et al.
Published: (2001)

Mass azithromycin for prevention of child mortality among children with acute malnutrition: A subgroup analysis of a cluster randomized controlled trial.
by: Ali Sié, et al.
Published: (2024)

Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds.
by: Elizabeth N Ssemanda, et al.
Published: (2012)

Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR)
by: Kieran S. O'Brien, et al.
Published: (2021)

Serology for trachoma surveillance after cessation of mass drug administration.
by: Diana L Martin, et al.
Published: (2015)

Household willingness to pay for azithromycin treatment for trachoma control in the United Republic of Tanzania
by: Frick Kevin D., et al.
Published: (2003)

Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 months into a trachoma mass drug administration campaign to reduce child mortality in Côte d'Ivoire.
by: Lisa Dulli, et al.
Published: (2024)

Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 months into a trachoma mass drug administration campaign to reduce child mortality in Côte d'Ivoire
by: Lisa Dulli, et al.
Published: (2024)

Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial.
by: Abdou Amza, et al.
Published: (2014)

Correction: Mass Treatment with Azithromycin for Trachoma: When Is One Round Enough? Results from the PRET Trial in The Gambia
Published: (2013)

Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trial
by: Ahmed M. Arzika, et al.
Published: (2023)

Short-term Forecasting of the Prevalence of Trachoma: Expert Opinion, Statistical Regression, versus Transmission Models.
by: Fengchen Liu, et al.
Published: (2015)

Identifying a sufficient core group for trachoma transmission.
by: Thomas M Lietman, et al.
Published: (2018)

Reliability of trachoma clinical grading--assessing grading of marginal cases.
by: Salman A Rahman, et al.
Published: (2014)

Correction: Short-term Forecasting of the Prevalence of Trachoma: Expert Opinion, Statistical Regression, versus Transmission Models.
by: Fengchen Liu, et al.
Published: (2015)

Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trial.
by: Ahmed M Arzika, et al.
Published: (2023)